Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker (OncoPhys)

Comparison of the Physical Activity Assessed by an Accelerometer and the International Physical Activity Questionnaire in Oncologic Patients

Physical activity is an important aspect of cancer therapy but correct measurement of physical activity is difficult. In this study, the physical activity of patients undergoing cancer therapy is assessed by questionnaire and by motion tracker. The results are then compared to answer whether there are differences between the two measurements. Findings of this study will help to improve the assessment of physical activity in cancer patients.

Study Overview

• Status: Recruiting
• Conditions: Lymphoma; Colorectal Cancer; Pancreas Cancer
• Intervention / Treatment: Other: No intervention - observational study only

Detailed Description

Although physical activity has been identified as a relevant determinant of cancer therapy outcome, its valid assessment remains challenging. In principle, direct and indirect assessment instruments can be employed for assessment of physical activity. While direct instruments, e.g. accelerometers, are considered to provide a more objective measurement, indirect tools such as questionnaires are less expensive and more applicable for use in larger study populations. The validity of both forms of measurements in cancer patients is however not well studied. Therefore, this study aims to elucidate the relative validity of an accelerometer in comparison to a standardized physical questionnaire at different time points of cancer therapy. Findings of this study will allow conclusions regarding the ideal modalities for assessment of physical activity in cancer patients.

• Study Type: Observational
• Enrollment (Estimated): 60

Contacts and Locations

• Study Contact: Name: Ali A Aghdassi, Professor; Phone Number: +493834867230; Email: ali.aghdassi@med.uni-greifswald.de

Study Locations

• Germany
  • Greifswald, Germany, 17475
    • Recruiting
    • University Medicine Greifswald
    • Contact: Ali A Aghdassi, Professor; Phone Number: +493834867230; Email: ali.aghdassi@med.uni-greifswald.de
    • Principal Investigator: Ali A Aghdassi, Professor
    • Sub-Investigator: Mats L Wiese, MSc
    • Sub-Investigator: Sebastian Schmidt

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients will be recruited at University Medicine Greifswald (Northeast Germany). Patients with the verified diagnosis of lymphoma, colerectal or pancreatic cancer requiring surgical, chemo or radio therapy will be identified in the respective wards or day care units of the hosptial.

Description

Inclusion Criteria:

• verified diagnosis of lymphoma, colorectal or pancreatic cancer
• requirement of surgical, chemo or radio therapy
• provision of informed consent

Exclusion Criteria:

• pregnancy
• inability to provide consent
• use of a rollator

Study Plan

How is the study designed?

Design Details

• Observational Models: Other
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Cancer Patients; Patients with a verified diagnosis of lymphoma, colorectal or pancreatic cancer requiring surgical, chemo or radio therapy.	Other: No intervention - observational study only; No intervention - observational study only

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comparison of physical activity assessments within 1 week after initiation of cancer therapy	Difference in physical activity measured by the GeneActiv accelerometer and the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)	1 week after initiation of cancer therapy

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comparison of physical activity assessments 12 weeks after initiation of cancer therapy	Difference in physical activity measured by the GeneActiv accelerometer and the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)	12 weeks after initiation of cancer therapy
Comparison of changes in physical activity between assessements within 1 week and 12 weeks after initiation of cancer therapy	Difference in changes of physical activity measured by the GeneActiv accelerometer and the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)	12 weeks after initiation of cancer therapy
Physical activity assessed by accelerometer	Physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)	1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Physical activity assessed by questionnaire	Physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)	1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of Eastern Co-operative Oncology Group (ECOG) Performance Status to physical activity assessed by accelerometer	Association between ECOG Performance Status and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)	1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of Eastern Co-operative Oncology Group (ECOG) Performance Status to physical activity assessed by questionnaire	Association between ECOG Performance Status and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)	1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of Karnofsky Performance Status (KPS) to physical activity assessed by accelerometer	Association between KPS and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)	1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of Karnofsky Performance Status (KPS) to physical activity assessed by questionnaire	Association between KPS and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)	1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of age to physical activity assessed by accelerometer	Association between age and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)	1 week after initiation of cancer therapy
Relation of age to physical activity assessed by questionnaire	Association between age and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)	1 week after initiation of cancer therapy
Relation of sex to physical activity assessed by accelerometer	Association between sex and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)	1 week after initiation of cancer therapy
Relation of sex to physical activity assessed by questionnaire	Association between sex and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)	1 week after initiation of cancer therapy
Relation of quality of life to physical activity assessed by accelerometer	Association between quality of life assessed by the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ C-30) and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)	1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of quality of life to physical activity assessed by questionnaire	Association between quality of life assessed by the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ C-30) and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)	1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Therapy-related quality of life	Association between quality of life assessed by the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ C-30) and cancer therapy modality	1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of fatigue to physical activity assessed by accelerometer	Association between fatigue assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Fatigue Questionnaire (EORTC QLQFA-12) and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)	1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of fatigue to physical activity assessed by questionnaire	Association between fatigue assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Fatigue Questionnaire (EORTC QLQFA-12) and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)	1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Therapy-related fatigue	Association between fatigue assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Fatigue Questionnaire (EORTC QLQFA-12) and cancer therapy modality	1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of sleep duration to physical activity assessed by accelerometer	Association between sleep duration measured by the GeneActiv accelerometer in hours and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)	1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of sleep duration to physical activity assessed by questionnaire	Association between sleep duration measured by the GeneActiv accelerometer in hours and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)	1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of sleep efficiency to physical activity assessed by accelerometer	Association between sleep efficiency, i.e. the ratio of sleep duration to total bed time measured by the GeneActiv accelerometer in hours, and physical activity measured by the GeneActiv accelerometer in metabolic equivalents of tasks (METs)	1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Relation of sleep efficiency to physical activity assessed by questionnaire	Association between sleep efficiency, i.e. the ratio of sleep duration to total bed time measured by the GeneActiv accelerometer in hours, and physical activity measured by the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)	1 week before initiation of cancer therapy, 1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Therapy-related sleep duration	Association between sleep duration measured by the GeneActiv accelerometer in hours and cancer therapy modality	1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Therapy-related sleep efficiency	Association between sleep efficiency, i.e. the ratio of sleep duration to total bed time measured by the GeneActiv accelerometer in hours, and cancer therapy modality	1 week after initiation of cancer therapy, 12 weeks after initiation of cancer therapy
Changes in fatigue between assessements before and 12 weeks after initiation of cancer therapy	Differences in fatigue assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Fatigue Questionnaire (EORTC QLQFA-12)	12 weeks after initiation of cancer therapy
Changes in quality of life between assessements before and 12 weeks after initiation of cancer therapy	Differences in quality of life assessed by the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ C-30)	12 weeks after initiation of cancer therapy
Relation of tumor entity to changes in physical activity between assessements within 1 week and 12 weeks after initiation of cancer therapy	Association between tumor entity and changes in physical activity measured by the GeneActiv accelerometer and the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)	12 weeks after initiation of cancer therapy
Relation of cancer therapy modality to changes in physical activity between assessements within 1 week and 12 weeks after initiation of cancer therapy	Association between cancer therapy modality and changes in physical activity measured by the GeneActiv accelerometer and the short version of the International Physical Activity Questionnaire (IPAQ-sf) in metabolic equivalents of tasks (METs)	12 weeks after initiation of cancer therapy

Collaborators and Investigators

• Sponsor: University Medicine Greifswald
• Investigators: Principal Investigator: Ali A Aghdassi, Professor, University Medicine Greifswald

Study record dates

Study Major Dates

• Study Start (Actual): September 21, 2022
• Primary Completion (Estimated): December 31, 2024
• Study Completion (Estimated): March 31, 2025

Study Registration Dates

• First Submitted: August 11, 2022
• First Submitted That Met QC Criteria: August 11, 2022
• First Posted (Actual): August 15, 2022

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: December 23, 2024
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Keywords: Physical Activity; Quality of Life; Fatigue; Cancer Therapy; Accelerometer; International Physical Activity Questionnaire; GeneActiv
• Additional Relevant MeSH Terms: Endocrine System Diseases; Neoplasms by Site; Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Endocrine Gland Neoplasms; Pancreatic Diseases; Pancreatic Neoplasms
• Other Study ID Numbers: BB 067/22

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No